The recent update to the EASL clinical practice guidelines for the diagnosis and management of patients with PBC is contributing to a change in perception of the disease and in understanding of how patients with PBC should be managed.

This educational symposium will explore the epidemiology, patient treatment and the emerging therapeutic options and the clinical impact of the new guidelines. We hope you will be able to join us for an interactive and engaging discussion about this evolving therapy area.

Breakfast will be provided.

This event has been organised and funded by Intercept Pharma Nederland BV
Kamperingweg 45d, 2803PE, Gouda (NL)
+31 182 71 50 57
info.benelux@interceptpharma.com
CHANGING PERSPECTIVES IN PRIMARY BILIARY CHOLANGITIS (PBC)

07:50 Breakfast served

08:00 Welcome and Introduction
Professor Frederik Nevens, UZ Leuven

08:05 Epidemiology of cholestatic liver disease in Belgium
Professor Christophe Moreno, Erasme Brussels

08:15 Painting the new treatment landscape: novel and emerging therapies for PBC
Professor Frederik Nevens

08:25 Panel discussion/Q&A
All faculty